However, a combination of CD44-targeted NIR-PIT and anti-PD-1 mAb was more effective compared to monotherapies with greater reduction of tumor progression, prolonged survival and an increased complete remission rate as high as 67%. This evidence concerns the gene PDCD1 and neoplasm.